Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Usefulness of serum interleukin-33 as a prognostic marker of severe traumatic brain injury.

Zhang ZY, Li J, Ye Q, Dong Y, Bao GM, Shen YK, Weng JF, Luo LF, Cen M.

Clin Chim Acta. 2019 Oct;497:6-12. doi: 10.1016/j.cca.2019.07.008. Epub 2019 Jul 4.

PMID:
31279693
2.

Analysis on Characteristics of ZnO Surface Acoustic Wave with and without Micro-Structures.

Huang HY, Chiang HJ, Wu CZ, Lin Y, Shen YK.

Micromachines (Basel). 2019 Jun 30;10(7). pii: E434. doi: 10.3390/mi10070434.

3.

Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study.

Gordon KB, Armstrong AW, Foley P, Song M, Shen YK, Li S, Muñoz-Elías EJ, Branigan P, Liu X, Reich K.

J Invest Dermatol. 2019 Jun 15. pii: S0022-202X(19)31755-5. doi: 10.1016/j.jid.2019.05.016. [Epub ahead of print]

PMID:
31207232
4.

Use of dose-exposure-response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis.

Lebwohl M, Langley RG, Zhu Y, Zhou H, Song M, Shen YK, Parnell Lafferty K, Reich K.

J Eur Acad Dermatol Venereol. 2019 May 11. doi: 10.1111/jdv.15668. [Epub ahead of print]

PMID:
31077471
5.

Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis.

Zhu Y, Marini JC, Song M, Randazzo B, Shen YK, Li S, Zhou H.

J Invest Dermatol. 2019 Aug;139(8):1830-1834.e6. doi: 10.1016/j.jid.2019.02.018. Epub 2019 Mar 6. No abstract available.

PMID:
30851300
6.

Hypergravity-assisted chemical liquid deposition of nano-granular film on the inner surface of a quartz tube.

Shen YK, He XQ, Gu X, Liu Z, He ZH.

R Soc Open Sci. 2018 Sep 26;5(9):180722. doi: 10.1098/rsos.180722. eCollection 2018 Sep.

7.

Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.

Reich K, Papp KA, Armstrong AW, Wasfi Y, Li S, Shen YK, Randazzo B, Song M, Kimball AB.

Br J Dermatol. 2019 May;180(5):1039-1049. doi: 10.1111/bjd.17454.

PMID:
30485400
8.
9.

Rhombic-Shaped Channel Stent with Enhanced Drug Capacity and Fatigue Life.

Hsiao HM, Lin CH, Shen YK, Chou TY, Hsu YY.

Micromachines (Basel). 2017 Dec 24;9(1). pii: E3. doi: 10.3390/mi9010003.

10.

The effect of anticoagulants on venous thrombosis prevention after knee arthroscopy: a systematic review.

Huang HF, Tian JL, Sun L, Yang XT, Shen YK, Li SS, Xie Q, Tian XB.

Int Orthop. 2018 Oct 30. doi: 10.1007/s00264-018-4212-4. [Epub ahead of print]

PMID:
30377699
11.

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.

Griffiths CEM, Papp KA, Kimball AB, Randazzo B, Song M, Li S, Shen YK, Blauvelt A.

J Drugs Dermatol. 2018 Aug 1;17(8):826-832.

PMID:
30124721
12.

Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.

Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A.

JAMA Dermatol. 2018 Jun 1;154(6):676-683. doi: 10.1001/jamadermatol.2018.0793.

13.

Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.

Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, You Y, Shen YK, Reich K.

J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1940-1949. doi: 10.1111/jdv.15012. Epub 2018 Jul 18.

PMID:
29706008
14.

Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.

Papp KA, Blauvelt A, Kimball AB, Han C, Randazzo B, Wasfi Y, Shen YK, Li S, Griffiths CEM.

J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1515-1522. doi: 10.1111/jdv.14910. Epub 2018 Apr 10.

15.

Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies.

Gordon KB, Blauvelt A, Foley P, Song M, Wasfi Y, Randazzo B, Shen YK, You Y, Griffiths CEM.

Br J Dermatol. 2018 Jan;178(1):132-139. doi: 10.1111/bjd.16008. Epub 2017 Dec 14.

PMID:
28940259
16.

Influence of Deformation and Stress between Bone and Implant from Various Bite Forces by Numerical Simulation Analysis.

Cheng HC, Peng BY, Chen MS, Huang CF, Lin Y, Shen YK.

Biomed Res Int. 2017;2017:2827953. doi: 10.1155/2017/2827953. Epub 2017 May 28.

17.

Surface Treatment on Physical Properties and Biocompatibility of Orthodontic Power Chains.

Cheng HC, Chen MS, Peng BY, Lin WT, Shen YK, Wang YH.

Biomed Res Int. 2017;2017:6343724. doi: 10.1155/2017/6343724. Epub 2017 Apr 30.

19.
20.

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.

Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K.

N Engl J Med. 2015 Jul 9;373(2):136-44. doi: 10.1056/NEJMoa1501646.

21.

Two-step thermal annealing improves the morphology of spin-coated films for highly efficient perovskite hybrid photovoltaics.

Hsu HL, Chen CP, Chang JY, Yu YY, Shen YK.

Nanoscale. 2014 Sep 7;6(17):10281-8. doi: 10.1039/c4nr02751e.

PMID:
25065461
22.

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.

Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB; PSUMMIT 2 Study Group.

Ann Rheum Dis. 2014 Jun;73(6):990-9. doi: 10.1136/annrheumdis-2013-204655. Epub 2014 Jan 30.

23.

Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS).

Zhu X, Zheng M, Song M, Shen YK, Chan D, Szapary PO, Wang B; LOTUS Investigators.

J Drugs Dermatol. 2013 Feb;12(2):166-74.

PMID:
23377389
24.

Synthesis and two-photon absorption property characterizations of small dendritic chromophores containing functionalized quinoxaliniod heterocycles.

Lin TC, Lee YH, Liu CY, Huang BR, Tsai MY, Huang YJ, Lin JH, Shen YK, Wu CY.

Chemistry. 2013 Jan 7;19(2):749-60. doi: 10.1002/chem.201202178. Epub 2012 Nov 21.

PMID:
23169324
25.

Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.

Tsai TF, Song M, Shen YK, Schenkel B, Choe YB, Kim NI, Lee JH, Lee JH, Song HJ, Youn JI; PEARL investigators.

J Drugs Dermatol. 2012 Aug;11(8):943-9.

PMID:
22859239
26.

The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.

Tsai TF, Ho V, Song M, Szapary P, Kato T, Wasfi Y, Li S, Shen YK, Leonardi C; PHOENIX 1, PHOENIX 2, ACCEPT, PEARL and Japanese Ustekinumab Study Groups.

Br J Dermatol. 2012 Nov;167(5):1145-52. doi: 10.1111/j.1365-2133.2012.11142.x.

PMID:
22803615
27.

Effect of Yiqi Bufei recipe [see text] on patients with pulmonary incompetence after pneumonectomy.

Yang Y, Shen YK, Zhou XM, Fu XQ, Mao WM, Dong LW, Wang J, Cheng GM.

Chin J Integr Med. 2011 Dec;17(12):898-902. doi: 10.1007/s11655-011-0817-9. Epub 2011 Jul 30.

PMID:
21805296
28.

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL).

Tsai TF, Ho JC, Song M, Szapary P, Guzzo C, Shen YK, Li S, Kim KJ, Kim TY, Choi JH, Youn JI; PEARL Investigators.

J Dermatol Sci. 2011 Sep;63(3):154-63. doi: 10.1016/j.jdermsci.2011.05.005. Epub 2011 May 20.

PMID:
21741220
29.

Brightness field distributions of microlens arrays using micro molding.

Cheng HC, Huang CF, Lin Y, Shen YK.

Opt Express. 2010 Dec 20;18(26):26887-904. doi: 10.1364/OE.18.026887.

PMID:
21196966
30.

Quantitative analysis of culture using millions of digitized books.

Michel JB, Shen YK, Aiden AP, Veres A, Gray MK; Google Books Team, Pickett JP, Hoiberg D, Clancy D, Norvig P, Orwant J, Pinker S, Nowak MA, Aiden EL.

Science. 2011 Jan 14;331(6014):176-82. doi: 10.1126/science.1199644. Epub 2010 Dec 16.

31.

Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial.

Kavanaugh A, Menter A, Mendelsohn A, Shen YK, Lee S, Gottlieb AB.

Curr Med Res Opin. 2010 Oct;26(10):2385-92. doi: 10.1185/03007995.2010.515804.

PMID:
20831455
32.

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.

Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, Silverman ED, Balogh Z, Henrickson M, Davidson J, Foeldvari I, Imundo L, Simonini G, Oppermann J, Xu S, Shen YK, Visvanathan S, Fasanmade A, Mendelsohn A, Martini A, Giannini EH; Paediatric Rheumatology INternational Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG).

Ann Rheum Dis. 2010 Apr;69(4):718-22. doi: 10.1136/ard.2009.100354. Erratum in: Ann Rheum Dis. 2011 Nov;70(11):2060. Ann Rheum Dis. 2012 Jun;71(6):1106.

33.

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A.

Lancet. 2009 Feb 21;373(9664):633-40. doi: 10.1016/S0140-6736(09)60140-9. Epub 2009 Feb 11. Erratum in: Lancet. 2009 Apr 18;373(9672):1340. Lancet. 2010 Nov 6;376(9752):1542.

PMID:
19217154
34.

DC-81-Indole conjugate agent induces mitochondria mediated apoptosis in human melanoma A375 cells.

Hu WP, Yu HS, Sung PJ, Tsai FY, Shen YK, Chang LS, Wang JJ.

Chem Res Toxicol. 2007 Jun;20(6):905-12. Epub 2007 May 26.

PMID:
17530784
35.

[Unrelated umbilical cord blood stem cell transplantation in a patient with chronic myelocytic leukemia].

Lin YD, Shen YK, Li YK.

Zhonghua Er Ke Za Zhi. 2006 Aug;44(8):586. Chinese. No abstract available.

PMID:
17083783
36.

Design, synthesis, and biological evaluation of pyrrolo[2,1-c][1,4]benzodiazepine and indole conjugates as anticancer agents.

Wang JJ, Shen YK, Hu WP, Hsieh MC, Lin FL, Hsu MK, Hsu MH.

J Med Chem. 2006 Feb 23;49(4):1442-9.

PMID:
16480280
37.
38.

Photosynthesis research in the People's Republic of China.

Kuang TY, Xu C, Li LB, Shen YK.

Photosynth Res. 2003;76(1-3):451-8.

PMID:
16228600
39.
40.

Site-directed Mutagenesis of epsilon Subunit of ATP Synthase of Maize Chloroplast.

Shi J, Wei JM, Shen YK.

Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 1998;30(5):483-487.

PMID:
12168018
41.
42.

Photoinactivation of photosystem II by cumulative exposure to short light pulses during the induction period of photosynthesis.

Shen YK, Chow WS, Park YI, Anderson JM.

Photosynth Res. 1996 Jan;47(1):51-9. doi: 10.1007/BF00017753.

PMID:
24301707
43.

Malate regulation of Mg(2+)-ATPase of chloroplast coupling factor 1.

Ren HM, Wei JM, Shen YK.

Photosynth Res. 1995 Jan;43(1):19-25. doi: 10.1007/BF00029458.

PMID:
24306635
44.

STUDIES ON PHOTOPHOSPHORYLATION. X. MECHANISM OF "OXIDATIVE PHOTOPHOSPHORYLATION".

SHEN GM, YANG SY, SHEN YK, YING HC.

Sci Sin. 1963 Sep;12:1406-8. No abstract available.

PMID:
14091077
45.

[Acute obstructive cholangitis].

SHEN YK, LIN YC, CHANG SD, CHENG KW, YU PC, HUNG HG.

Zhonghua Wai Ke Za Zhi. 1962 Oct;10:613-5. Chinese. No abstract available.

PMID:
13977126
46.

[Analysis of 179 cholangiograms in biliary tract surgery].

SHEN YK, CHEN YM, KU SS, YANG MO.

Zhonghua Wai Ke Za Zhi. 1962 Oct;10:631-4. Chinese. No abstract available.

PMID:
13977125
47.

[Preliminary reports on the synthetic materials for veins].

DUNG FC, SHEN YK, KU CY.

Zhonghua Wai Ke Za Zhi. 1962;10:46. Chinese. No abstract available.

PMID:
13888466
48.

Quantum requirement of photophosphorylation by isolated chloroplasts.

YIN HC, SHEN YK, SHEN GM, YANG SY, CHIU KS.

Sci Sin. 1961 Dec;10:976-84. No abstract available.

PMID:
14009113
49.

Surgical treatment of innominate aneurysm by shunt graft and excision.

FU PP, SHEN YK, LIN YC, CHANG TH.

Chin Med J. 1957 Apr;75(4):285-94. No abstract available.

PMID:
13437350

Supplemental Content

Support Center